US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. July 29, 2019

    Leaked Email In Price-Fixing Case Is Privileged, Heritage Says

    Heritage Pharmaceuticals told a Pennsylvania federal court Friday that an email it turned over to Connecticut's attorney general that was later used in the sprawling generic drug price-fixing litigation is privileged and should have been treated as confidential.

  2. July 22, 2019

    Conn. Denies Leaking Heritage Doc In Generic-Drug Case

    Connecticut's attorney general, one of several state AGs suing generic-drug companies alleging that they fixed prices, is defending the decision to refer in the complaint to an email suggesting Heritage Pharmaceuticals and other firms tried to obstruct a congressional probe into the generic-drug industry.

  3. July 10, 2019

    Heritage Says Conn. Leaked Email About Congressional Probe

    Heritage Pharmaceuticals accused Connecticut's attorney general on Tuesday of including a privileged email in a new generic-drug price-fixing complaint that suggests the company tried to obstruct a congressional investigation.

  4. June 26, 2019

    McKesson Dodges Generic Drug Price-Fix MDL For Now

    A Pennsylvania federal judge nixed claims Wednesday that McKesson Corp. earned billions of dollars by cooperating with an industry-wide price-fixing conspiracy among generic-drug makers, ruling that a putative class' allegations in the multidistrict litigation are impermissible suppositions.

  5. June 25, 2019

    Big Pharma's Biggest New Cases Of 2019: Midyear Report

    Multibillion-dollar lawsuits targeting major drugmakers emerged with astonishing frequency during the first half of 2019, threatening civil and criminal liability for all manner of alleged wheeling and dealing. Here, Law360 highlights the latest developments and upcoming action in the pharmaceutical world's hottest new cases.

  6. June 24, 2019

    Drugmakers' Emails, Calls Show Price-Fix Coverup, AGs Say

    Unredacted emails and phone records show Teva Pharmaceuticals, Pfizer Inc. and 18 other major U.S. drug manufacturers conspiring in an industrywide price-fixing scheme to keep the cost of hundreds of generic drugs artificially high, according to a complaint unsealed Monday by the Maryland attorney general's office.

  7. June 07, 2019

    States Call For Unredacting Of Their Generic-Drug Pricing Suit

    The attorneys general of 44 states and Puerto Rico want a Pennsylvania federal judge to make public an unredacted version of their suit accusing major drugmakers of orchestrating a sprawling scheme to fix the price of generics, saying the suit's subject matter was of "paramount public significance."

  8. June 04, 2019

    44 States' Generic-Drug Pricing Suit Rolled Into Pa. MDL

    A lawsuit filed in Connecticut last month by 44 state attorneys general accusing drugmakers of a sprawling scheme to fix generic-drug prices was transferred Tuesday to the Pennsylvania federal court overseeing multidistrict litigation over pricing in the industry.

  9. June 03, 2019

    Drugmakers Want AGs' Generics Price-Fixing Claims Tossed

    Pharmaceutical companies including Actavis, Teva and Mylan have asked a Pennsylvania federal court to dismiss state law claims by 47 state attorneys general against them in multidistrict litigation accusing them of price-fixing generic drugs.

  10. May 16, 2019

    United, Humana Say Classes Can't Carve Up Generic Awards

    United Healthcare and Humana want the Pennsylvania federal court overseeing sprawling multidistrict litigation over generic drug prices to refuse to grant an order that would set aside part of any money the health care companies might win for the main class.